Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) is focused on the research, development and commercialization of antiinfective products that address unmet medical needs in the acute care environment. CUBICIN® (daptomycin for injection), our first in class IV antibiotic, has experienced the most successful IV antibiotic launch, in dollar terms, in U.S. history. A comparison with historical sales trends demonstrates the significant growth potential for CUBICIN.
What's next for Cubist?
We are investing both in the optimization of CUBICIN and in "Act 2" for Cubist as a growing acute care biopharmaceutical company. We have recently announced that we have in-licensed from Dyax Corp. the U.S. and EU rights to develop and commercialize the clinical stage recombinant human protein DX-88 for I.V. use in the prevention of blood loss during surgery. The lead indication in this field, which is currently in Phase 2 clinical studies, is for use in patients undergoing on-pump cardio-thoracic surgery (CTS). We believe that the market opportunity for DX-88 is more than $500 Million in the U.S. and EU.
We are moving towards at least two IND filings this year: for our CB-138372 compound in development as Hepatitis C virus (HCV) therapy, as well as for an antibiotic in development for CDAD. We also continue to move forward with our pre-clinical program to develop much needed new therapy for treating serious infections caused by Gram-negative bacteria.